These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28756770)

  • 1. Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells.
    Geng R; Tan X; Zuo Z; Wu J; Pan Z; Shi W; Liu R; Yao C; Wang G; Lin J; Qiu L; Huang W; Chen S
    Chin J Cancer; 2017 Jul; 36(1):63. PubMed ID: 28756770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNF183 promotes proliferation and metastasis of colorectal cancer cells via activation of NF-κB-IL-8 axis.
    Geng R; Tan X; Wu J; Pan Z; Yi M; Shi W; Liu R; Yao C; Wang G; Lin J; Qiu L; Huang W; Chen S
    Cell Death Dis; 2017 Aug; 8(8):e2994. PubMed ID: 28796265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells.
    Zhou S; Xia H; Xu H; Tang Q; Nie Y; Gong QY; Bi F
    J Exp Clin Cancer Res; 2018 Sep; 37(1):218. PubMed ID: 30185207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
    Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
    Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
    Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
    Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
    Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
    BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer.
    Chen J; Dai J; Kang Z; Yang T; Zhao Q; Zheng J; Zhang X; Zhang J; Xu J; Sun G; Yang L; Yang T
    Exp Cell Res; 2020 Aug; 393(1):112060. PubMed ID: 32407729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
    Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ST13, a proliferation regulator, inhibits growth and migration of colorectal cancer cell lines.
    Bai R; Shi Z; Zhang JW; Li D; Zhu YL; Zheng S
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):884-93. PubMed ID: 23125081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
    J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
    Kan G; Wang Z; Sheng C; Chen G; Yao C; Mao Y; Chen S
    Adv Sci (Weinh); 2021 May; 8(10):2004344. PubMed ID: 34026451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
    Wagner S; Vlachogiannis G; De Haven Brandon A; Valenti M; Box G; Jenkins L; Mancusi C; Self A; Manodoro F; Assiotis I; Robinson P; Chauhan R; Rust AG; Matthews N; Eason K; Khan K; Starling N; Cunningham D; Sadanandam A; Isacke CM; Kirkin V; Valeri N; Whittaker SR
    Oncogene; 2019 Mar; 38(10):1717-1733. PubMed ID: 30353166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
    Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
    Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.
    Yang Y; Weng W; Peng J; Hong L; Yang L; Toiyama Y; Gao R; Liu M; Yin M; Pan C; Li H; Guo B; Zhu Q; Wei Q; Moyer MP; Wang P; Cai S; Goel A; Qin H; Ma Y
    Gastroenterology; 2017 Mar; 152(4):851-866.e24. PubMed ID: 27876571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
    Wang D; Fu L; Sun H; Guo L; DuBois RN
    Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.
    Zhang Y; Talmon G; Wang J
    Cell Death Dis; 2015 Aug; 6(8):e1845. PubMed ID: 26247730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
    Wu L; Zhang J; Wu H; Han E
    Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.